Cargando…

In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study

BACKGROUND: Calculation of individual risk is the cornerstone of effective cardiovascular prevention. arriba is a software to estimate the individual risk to suffer a cardiovascular event in 10 years. Prognosis and the absolute effects of pharmacological and lifestyle interventions help the patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Diener, Annette, Celemín-Heinrich, Salomé, Wegscheider, Karl, Kolpatzik, Kai, Tomaschko, Katrin, Altiner, Attila, Donner-Banzhoff, Norbert, Haasenritter, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583804/
https://www.ncbi.nlm.nih.gov/pubmed/23339773
http://dx.doi.org/10.1186/1471-2296-14-13
_version_ 1782475483152121856
author Diener, Annette
Celemín-Heinrich, Salomé
Wegscheider, Karl
Kolpatzik, Kai
Tomaschko, Katrin
Altiner, Attila
Donner-Banzhoff, Norbert
Haasenritter, Jörg
author_facet Diener, Annette
Celemín-Heinrich, Salomé
Wegscheider, Karl
Kolpatzik, Kai
Tomaschko, Katrin
Altiner, Attila
Donner-Banzhoff, Norbert
Haasenritter, Jörg
author_sort Diener, Annette
collection PubMed
description BACKGROUND: Calculation of individual risk is the cornerstone of effective cardiovascular prevention. arriba is a software to estimate the individual risk to suffer a cardiovascular event in 10 years. Prognosis and the absolute effects of pharmacological and lifestyle interventions help the patient make a well-informed decision. The risk calculation algorithm currently used in arriba is based on the Framingham risk algorithm calibrated to the German setting. The objective of this study is to evaluate and adapt the algorithm for the target population in primary care in Germany. METHODS/DESIGN: arriba-pro will be conducted within the primary care scheme provided by a large health care insurer in Baden-Württemberg, Germany. Patients who are counseled with arriba by their general practitioners (GPs) will be included in the arriba-pro cohort. Exposure data from the consultation with arriba such as demographic data and risk factors will be recorded automatically by the practice software and transferred to the study centre. Information on relevant prescription drugs (effect modifiers) and cardiovascular events (outcomes) will be derived from administrative sources. DISCUSSION: The study is unique in simulating a therapy naïve cohort, matching exactly research and application setting, using a robust administrative data base, and, finally, including patients with known cardiovascular disease who have been excluded from previous studies. TRIAL REGISTRATION: The study is registered with Deutsches Register Klinischer Studien (DRKS00004633).
format Online
Article
Text
id pubmed-3583804
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35838042013-02-28 In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study Diener, Annette Celemín-Heinrich, Salomé Wegscheider, Karl Kolpatzik, Kai Tomaschko, Katrin Altiner, Attila Donner-Banzhoff, Norbert Haasenritter, Jörg BMC Fam Pract Study Protocol BACKGROUND: Calculation of individual risk is the cornerstone of effective cardiovascular prevention. arriba is a software to estimate the individual risk to suffer a cardiovascular event in 10 years. Prognosis and the absolute effects of pharmacological and lifestyle interventions help the patient make a well-informed decision. The risk calculation algorithm currently used in arriba is based on the Framingham risk algorithm calibrated to the German setting. The objective of this study is to evaluate and adapt the algorithm for the target population in primary care in Germany. METHODS/DESIGN: arriba-pro will be conducted within the primary care scheme provided by a large health care insurer in Baden-Württemberg, Germany. Patients who are counseled with arriba by their general practitioners (GPs) will be included in the arriba-pro cohort. Exposure data from the consultation with arriba such as demographic data and risk factors will be recorded automatically by the practice software and transferred to the study centre. Information on relevant prescription drugs (effect modifiers) and cardiovascular events (outcomes) will be derived from administrative sources. DISCUSSION: The study is unique in simulating a therapy naïve cohort, matching exactly research and application setting, using a robust administrative data base, and, finally, including patients with known cardiovascular disease who have been excluded from previous studies. TRIAL REGISTRATION: The study is registered with Deutsches Register Klinischer Studien (DRKS00004633). BioMed Central 2013-01-22 /pmc/articles/PMC3583804/ /pubmed/23339773 http://dx.doi.org/10.1186/1471-2296-14-13 Text en Copyright ©2013 Diener et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Diener, Annette
Celemín-Heinrich, Salomé
Wegscheider, Karl
Kolpatzik, Kai
Tomaschko, Katrin
Altiner, Attila
Donner-Banzhoff, Norbert
Haasenritter, Jörg
In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study
title In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study
title_full In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study
title_fullStr In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study
title_full_unstemmed In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study
title_short In-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study
title_sort in-vivo-validation of a cardiovascular risk prediction tool: the arriba-pro study
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583804/
https://www.ncbi.nlm.nih.gov/pubmed/23339773
http://dx.doi.org/10.1186/1471-2296-14-13
work_keys_str_mv AT dienerannette invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy
AT celeminheinrichsalome invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy
AT wegscheiderkarl invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy
AT kolpatzikkai invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy
AT tomaschkokatrin invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy
AT altinerattila invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy
AT donnerbanzhoffnorbert invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy
AT haasenritterjorg invivovalidationofacardiovascularriskpredictiontoolthearribaprostudy